1. No category

Physiology & Behavior 119 (2013) 145–148
Contents lists available at SciVerse ScienceDirect
Physiology & Behavior
journal homepage: www.elsevier.com/locate/phb
Effects of long-term etanercept treatment on anxiety- and depression-like
neurobehaviors in rats
Dilek Bayramgürler a,1, Ayşe Karson b,1, Cüneyt Özer c,1, Tijen Utkan c,d,⁎,1
a
Kocaeli University Medical School, Department of Dermatology, Kocaeli, Turkey
Kocaeli University Medical School, Department of Physiology, Kocaeli, Turkey
Kocaeli University, Experimental Medical Research and Application Centre, Kocaeli, Turkey
d
Kocaeli University Medical School, Department of Pharmacology, Kocaeli, Turkey
b
c
H I G H L I G H T S
•
•
•
•
Etanercept decreased anxiety-like neurobehaviors of rats.
Etanercept decreased depressive-like neurobehaviors.
Etanercept did not affect locomotor activity.
These findings point to role for TNF-α in the modulation of emotional processes.
a r t i c l e
Article history:
Received 4 April 2013
Accepted 5 June 2013
Keywords:
Etanercept
Inflammation
TNF-α
Forced swimming
Elevated plus maze
i n f o
a b s t r a c t
Growing evidence indicates that there is a correlation between depression and inflammation. Administration of
anti-tumor necrosis factor (TNF) agents for treatment of chronic inflammatory diseases, such as psoriasis, was
associated with decreased depressive symptoms and increased quality of life in some clinical studies. The aim
of the present study was to investigate the effects of chronic etanercept, a TNF-α inhibitor, on anxiety- and
depression-like neurobehaviors in rats.
Male rats were treated for 8 weeks with either saline or etanercept (0.8 mg/kg/week, subcutaneously). The
anxiety levels of rats were evaluated using the elevated plus maze, a classical rodent model of anxiety and
depression was measured using the force swimming test, a behavioral despair task.
The anxiety-like neurobehaviors of the animals were found significantly decreased after the etanercept treatment.
Etanercept significantly decreased immobility time in rat model of despair test, seemed to have an antidepressive
effect in rats. Compared to saline treatment, long-term etanercept treatment had no effect on the total number
and pattern of locomotor activities.
Findings of the study supported the hypothesis that TNF-α has a role in the modulation of emotional processes
and its inhibition may represent a novel strategy for the treatment of affective disorders.
© 2013 Elsevier Inc. All rights reserved.
1. Introduction
A growing number of studies show high co-morbidity of anxiety
and depression with chronic inflammatory diseases such as psoriasis
and rheumatoid arthritis [1,2]. The relationship between depression
and/or anxiety and chronic inflammatory diseases can be explained
in several different manners. One explanation is that several circulating proinflammatory cytokines such as tumor necrosis factor-alpha
(TNF-α) are implicated in the origin of both conditions [3]. Moreover,
⁎ Corresponding author at: Experimental Medical Research and Application Centre and
Department of Pharmacology, Kocaeli University Medical School, Kocaeli 41380, Turkey.
Tel.: +90 262 3037460; fax: +90 262 3037004.
E-mail address: [email protected] (T. Utkan).
1
These authors equally contributed to this work.
0031-9384/$ – see front matter © 2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.physbeh.2013.06.010
it has been suggested that proinflammatory cytokines contribute to
the development of depressive disorder and induce true major depressive disorders in physically ill patients with no history of mental disorders [4]. Data indicate that activation of the inflammatory response
leads to release of inflammatory cytokines and mobilization of immune
cells both of which have been shown to access the brain and alter behavior [5]. This is regarded as evidence that inflammation is an important
biological event that can increase the risk of major depressive episodes,
much like the more traditional psychosocial factors [6]. Consistently, administration of anti-TNF agents for the treatment of these chronic inflammatory diseases was associated with decreased depressive symptoms
and increased health-related quality of life in addition to alleviation of
disease symptoms [3,7–10]. Although these studies suggested that treatment with anti-TNF agents reduces symptoms of depression, it is not
clear whether improvement in psychiatric pathology can be attributed
146
D. Bayramgürler et al. / Physiology & Behavior 119 (2013) 145–148
to the primary effect of TNF-α inhibition or a consequence of clinical remission. Moreover, our previous study showed that chronic treatment
with infliximab, a TNF-α inhibitor, significantly decreased the immobility
time in forced swim in chronically stressed rats, indicating a possible
antidepressant-like effect, as well as anxiolytic effect [11]. Therefore, we
decided to explore whether long-term etanercept treatment could affect
the anxiety- and depression-like neurobehaviors in rats without a chronic
inflammatory or stressful condition by various behavioral methods.
2. Materials and methods
2.1. Animals
Subjects were adult male Wistar albino rats weighing 300–400 g.
Animals were maintained under standard laboratory conditions on a
12/12-h light/dark cycle (lights on at 7:00 AM). Tap water and food
pellets were provided ad libitum. The experiments reported in this
study were conducted in accordance with the Regulation of Animal
Research Ethics Committee in Turkey (6 July 2006, Number 26220).
Ethical approval was granted by the Kocaeli University Animal Research
Ethics Committee (Kocaeli, Turkey).
All animals used in this study were naive to the experimental tests.
Rats were allocated to the following study groups: animals treated
with saline (control group, n = 9) and animals treated with etanercept
(etanercept group, n = 9). Etanercept (Wyeth, Münster, Germany)
was dissolved in physiological saline and injected subcutaneously at a
dose of 0.8 mg/kg. Drug dosage was chosen according to the previous
clinical and experimental studies. Drug solutions were freshly prepared prior to use once a week for 8 weeks since efficacy of classical
antidepressants appears after long term usage in forced swimming
test. Behavioral tests were started 3 days after the last injection
and performed on different days in the following order: locomotor
activity, the elevated plus maze and forced swimming. All experiments were conducted between 09:00 AM and 12:00 PM.
2.2. Behavioral tests
2.2.1. Locomotor activity
Locomotor activity was assessed using an animal activity monitoring system (Commat Ltd., Ankara, Turkey), which was composed of a
Plexiglas chamber, a computer, and open field activity software. The
Plexiglas chamber (42 × 42 × 30 cm) was equipped with infrared
photocells, and pairs of 15 infrared photobeams and detectors were
mounted horizontally every 2.5 cm (bottom) and vertically every
4.5 cm (upper). Interruptions of photocell beams were detected by
the computer system. Locomotor activity was recorded as stereotypic
(repeated beam breaks at the same photobeams), vertical (breaks in
the upper set of photobeams), and ambulatory (breaking more than
1 consecutive photobeam in the bottom set of photobeams) activities.
Total locomotor activity is expressed as the sum of stereotypic, ambulatory, and vertical activities. The activity was monitored continuously
for 10 min following acclimatization to the test room for a period of
1 h.
2.2.2. Elevated plus maze
Anxiety-like neurobehavior was evaluated in the elevated plus
maze apparatus, which was made of wood and consisted of 2 open
arms (50 × 10 cm) and 2 closed arms (50 × 10 cm) connected by a
central square (10 × 10 cm) and elevated to a height of 50 cm.
Rats were placed individually in the center of the maze facing a
closed arm and allowed 5 min of free exploration. The rat was considered to have entered an arm when all 4 limbs were inside the
arm. The apparatus was cleaned with ethanol solution after each
test. The percentage of time spent on the open arms and open arm
entries was calculated.
2.2.3. Forced swimming test
The forced swimming test apparatus was a cylinder (height, 47 cm;
inside diameter, 38 cm) containing 38 cm of tap water maintained at
22 ± 1 °C. The experimental session consisted of 2 trials: conditioning
and test. During the conditioning trial, rats were gently placed into the
cylinder for 15 min. After the trial, rats were dried and placed into a
warm cage with paper towels for 10–15 min before being returned to
their home cages. The test trial was carried out 24 h later. Rats were
placed again into the cylinder for a 5-min test session. Following the
swim session, rats were removed from the cylinder, dried with a towel,
and placed underneath a heating lamp for approximately 30 min before
being returned to their home cages. Tests were videotaped. The immobility time, which was defined as the lack of motion of the whole body
except for the small movements necessary to keep the animal's head
above the water, was recorded. The observer blind to the treatment conditions recorded the time spent immobile in the test session.
2.3. Statistical analysis
Results are expressed as mean ± SEM. Student's t test was used
for comparisons between groups. P values of b0.05 were considered
statistically significant.
3. Results
3.1. Effects of long-term etanercept treatment on locomotor activity
The locomotor activity of rats was measured in a 10-min trial
conducted on the third day of the last drug injection. Etanercept had
no effect on total locomotor activity [t(18) = 0.62; P = 0.54] or percent
of resting time [t(16) = 0.39; P = 0.69], indicating that the effects of
etanercept on emotional tests do not result from its effects on locomotor
activities (Table 1). Similar results were found when we analyzed further
components of the animals' locomotor activity, including ambulatory
[t(16) = 0.72; P = 0.48], vertical [t(16) = 1.62; P = 0.12], and stereotypic [t(16) = 0.43; P = 0.67] activities (Table 1).
3.2. Effects of long-term etanercept treatment on anxiety-like neurobehavior
in the elevated plus maze test
Elevated plus maze tests were conducted on the fourth day of the last
drug injection. The etanercept-treated group spent a larger percentage of
time in the open arms [t(18) = 4.13; P b 0.001] (Fig. 1A) and exhibited a
higher proportion of open arm entries [t(18) = 2.34; P b 0.05] than the
control group did (Fig. 1B).
3.3. Effects of long-term etanercept treatment on depression-like
neurobehavior in the forced swimming test
Forced swimming test was conducted for the assessment of
depressive-like behavior (despair) on the 5th and 6th days of the last
drug injection. On the first day of forced-swim testing, the immobility
time of etanercept-treated rats did not differ from that of the controls
[t(16) = 1.43; P = 0.17] (Fig. 2). However, etanercept-treated rats
exhibited significantly less immobility than that of the controls on the
second day of testing [t(16) = 5.24; P b 0.0001] (Fig. 2).
4. Discussion
Long-term etanercept treatment significantly decreased anxietyand depressive-like neurobehaviors of rats as assessed with elevated
plus maze and forced swimming tests, respectively. Etanercept did not
alter total locomotor activity levels, which indicated that differences
observed in emotional tests were not mediated by the psychomotor
activation of etanercept.
D. Bayramgürler et al. / Physiology & Behavior 119 (2013) 145–148
147
Table 1
Effect of chronic etanercept treatment on the locomotor activities of the rats.
Groups
Stereotypic activity
Vertical activity
Ambulatory activity
Total activity
% resting
Saline
Etanercept
592.8 ± 48.40
618.3 ± 33.82
15.13 ± 1.576
20.25 ± 2.732
39.63 ± 17.71
57.88 ± 18.13
648.1 ± 56.56
696.4 ± 52.59
73.0 ± 2.24
71.5 ± 3.08
There was no difference between the groups in total activity and percentage of resting time compared with saline as well as in stereotypic, ambulatory, or vertical activity (all Ps > 0.5).
Values depict mean ± SEM.
Recent neurobiological studies have revealed that cytokines are
involved in the development and maintenance of mood disorders.
According to the so-called ‘cytokine hypothesis of depression’, cytokines
represent the key factors in the central mediation of the behavioral,
neuroendocrine, and neurochemical features of depressive disorders
[12,13]. Of the major proinflammatory cytokines, TNF-α is particularly
interesting with respect to major depression. Both TNF-α and its receptor levels are significantly elevated in acutely depressed patients [4],
and improvement of depression correlates with decreases in serum
levels of TNF-α [14]. Preclinical studies also support these findings. In
animals, it was shown that anxiety and/or depressive-like behaviors
were induced by both TNF-α and inducers such as lipopolysaccharide
administration or chronic mild stress (CMS) [15–21]. Consistently, antidepressant treatment has been shown to decrease TNF-α level both in
humans and animals [22–24]. All these evidence suggest that there is
an association between pro-inflammatory cytokines and depression but
the mechanisms by which inflammation affects mood are only partially
understood.
In recent years, several studies have suggested that treatment with
anti-TNF agents for psoriasis also reduces symptoms of depression in
these patients [3,7–9]. First, a prospective clinical study reported by
Tyring and co-workers [7] demonstrated that compared to placebo
administration, etanercept treatment led to an improvement of at least
50% in depression rating scales at week 12. However, the improvement
in symptoms of depression was not strongly correlated with the improvement in psoriasis area and severity index (PASI) in this study [7].
% time spent in open arms
A
80
***
60
40
20
0
% open arm entries
B 80
*
60
40
20
0
Saline
Etanercept
Fig. 1. Effects of chronic etanercept treatments on the anxiety-like behavior in elevated
plus maze. Etanercept treated group spent more time (percentage) in the open arms
and exhibited higher proportion of open arm entries. * depicts P b 0.05, *** depicts
P b 0.001. Values depict mean ± SEM.
Subsequently, Bassukas and co-workers [9] reported that treatment
with infliximab resulted in stabilization or improvement of the manifestations of psychiatric morbidity in 3 psoriasis patients with overt psychiatric disorders, including recurrent depression and bipolar disorder.
Finally, Menter et al. [3] showed that adalimumab treatment reduced
symptoms of depression and improved health-related quality of life
in addition to improving psoriasis. In contrast to Tyring et al. [7], they
reported that reductions in depression symptoms were correlated
with PASI [3]. Although these studies have suggested that treatment
with anti-TNF agents for psoriasis reduces symptoms of depression,
none of these studies could distinguish whether anti-TNF agents had
a direct or indirect effect (a secondary effect representing alleviation
of psoriasis) on depression. Several animal studies have shown that
cytokine-induced sickness behaviors, which are similar to depressivelike behaviors, can be attenuated by TNF-α blockage [16,17]. Consistent
with clinical observations that point at the antidepressant efficacy
of TNF alpha inhibitors, we reported that chronic administration of
infliximab decreased CMS-induced depression-like behaviors in rats
[11].
The common outcome of all these studies is that, inflammation
could lead to depression symptoms and TNF-α inhibition could display
antidepressant/anxiolytic action in chronic inflammatory diseases. On
the other hand, the effects of TNF-α inhibition on the anxiety and
depression independently of chronic inflammation have not been evaluated. In order to clarify this topic, we used depression and anxiety tests
which are commonly used in preclinical investigation, in the naive rats.
In this context, our results, that showed a reduction in anxiety and
depressive-like symptoms after chronic etanercept treatment are
novel and might have a base for future studies for investigation of
underlying mechanisms of the antidepressant and anxiolytic effects
of anti-TNF agents.
In order to clarify the anti-depressive effects of TNF-α inhibitors,
several mechanisms could be speculated based on previous studies:
(1) TNF-α might acutely regulate neuronal serotonin transporter
activity [7,25]. (2) Immune activation with increased production of
pro-inflammatory cytokines activates the tryptophan and serotonindegrading enzyme indoleamine-2,3-dioxygenase. (3) TNF-α might play
a causative role in depression-related activation of the hypothalamus–
pituitary–adrenal axis [26]. Therefore, etanercept as a TNF-α inhibitor,
might block the depressive and anxiety-like behaviors by interacting
with one or more plausible peripheral mechanisms maintained above
and others such as modulation of hypothalamic pituitary adrenal axis
and vagal activity [27,28].
The antidepressant and anxiolytic effects of etanercept could be
attributed to either its chronic effects on the baseline circumstances
modulating the emotional and behavioral responses to acute stressors
or its acute effects on possibly higher TNF-α levels after the acute stress.
Although, elevated plus maze and forced swimming tests are acute
models of the anxiety and depression, efficacy of classical antidepressants usually requires long-term treatment in the forced swimming
test indicating that antidepressant actions of these drugs are due to
neuroplastic changes capable of modifying the stress-induced response
[29–31]. Based on this evidence, we can also argue that the action
pattern of etanercept may resemble those of antidepressant drugs
(especially selective serotonin reuptake inhibitors). As a second possibility, etanercept could inhibit TNF-α induced by procedures applied
during behavioral tests. Although, CMS that is used to establish
D. Bayramgürler et al. / Physiology & Behavior 119 (2013) 145–148
10
Immobility time (min)
Immobility time (min)
148
8
6
4
2
0
1.5
1.0
0.5
****
0.0
First day
Second day
Saline
Etanercept
Fig. 2. Effects of chronic etanercept treatments on the depression-like behavior in forced swimming test. Etanercept significantly decreased the immobility time of the FST on the
second day. **** depicts P b 0.0001. Values depict mean ± SEM.
depression has been shown to increase TNF-α levels [20,21], to our
knowledge there is no information regarding the effects of elevated
plus maze or forced swimming tests on TNF-α levels. The measurement
of TNF-α level after these tests is needed.
5. Conclusion
Our results showed that etanercept treatment reduced the anxiety
and depressive-like symptoms of rats in the absence of a chronic inflammatory or stressful condition, which is consistent with the clinical
studies mentioned above. This indicates that new indications for TNF-α
blockers will emerge in the future. The acute effects of these agents on
emotional symptoms and the underlying mechanisms remain to be
investigated.
Acknowledgments
This study was supported by a grant from Kocaeli University Research
Fund (Project Number: 2011/58), presented as an oral presentation and
won the First Prize in the Best Oral Presentation at the 20th Prof. Dr. A.
Lutfu Tat Symposium, 16–20 November, 2011, Ankara, Turkey.
References
[1] Hayes J, Koo J. Psoriasis: depression, anxiety, smoking, and drinking habits.
Dermatol Ther 2010;23:174–80.
[2] Covic T, Cumming SR, Pallant JF, Manolios N, Emery P, et al. Depression and anxiety in
patients with rheumatoid arthritis: prevalence rates based on a comparison of the
Depression, Anxiety and Stress Scale (DASS) and the Hospital, Anxiety and Depression Scale (HADS). BMC Psychiatry 2012;12:6.
[3] Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, et al. The effect of
adalimumab on reducing depression symptoms in patients with moderate to severe
psoriasis: a randomized clinical trial. J Am Acad Dermatol 2010;62:812–8.
[4] Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, et al. Depression, comorbidities and the TNF-alpha system. Eur Psychiatry 2008;23:421–9.
[5] Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact
on neurotransmitters and neurocircuits. Depress Anxiety 2013. http://dx.doi.org/
10.1002/da.22084.
[6] Danzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to
sickness and depression: when the immune system subjugates the brain. Nat Rev
Neurosci 2008;9:46–56.
[7] Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled
randomised phase III trial. Lancet 2006;367:29–35.
[8] Bassukas ID, Hyphantis T, Gamvroulia C, Gaitanis G, Mavreas V. Infliximab for patients with plaque psoriasis and severe psychiatric comorbidity. J Eur Acad Dermatol
Venereol 2008;22:257–8.
[9] Yip L, Harrison S, Foley P. Infliximab rescue of efalizumab withdrawal flare and
psoriasis-precipitated depression. Australas J Dermatol 2008;49:250–1.
[10] Uguz F, Akman C, Kucuksarac S, Tufekci O. Anti-tumor necrosis factor-alpha therapy
is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis. Psychiatry Clin Neurosci 2009;63:50–5.
[11] Karson A, Demirtaş T, Bayramgurler D, Balcı F, Utkan T. Chronic administration of
infliximab (TNF-α inhibitor) decreases depression and anxiety-like behaviour in rat
model of chronic mild stress. Basic Clin Pharmacol Toxicol 2012. http://dx.doi.org/
10.1111/bcpt.12037.
[12] Miller DB, O'Callaghan JP. Depression, cytokines, and glial function. Metabolism
2005;54:33–8.
[13] Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog
Neuropsychopharmacol Biol Psychiatry 2005;29:201–17.
[14] Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and
treatment response in major depressive disorder. Neuropsychopharmacology
2000;22:370–9.
[15] Grippo AJ, Francis J, Beltz TG, Felder RB, Johnson AK. Neuroendocrine and cytokine
profile of chronic mild stress-induced anhedonia. Physiol Behav 2005;84:697–706.
[16] Bluthé RM, Layé S, Michaud B, Layé S. Role of interleukin-1 beta and tumour necrosis
factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with
interleukin-1 type I receptor-deficient mice. Eur J Neurosci 2000;12:4447–56.
[17] Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, Avitsur R, et al. Illness,
cytokines, and depression. Ann N Y Acad Sci 2000;917:478–87.
[18] Sah SP, Tirkey N, Kuhad A, Chopra K. Effect of quercetin on lipopolysaccharide
induced-sickness behavior and oxidative stress in rats. Indian J Pharmacol
2011;43:192–6.
[19] Peruga I, Hartwig S, Thöne J, Hovemann B, Gold R, Juckel G, et al. Inflammation
modulates anxiety in an animal model of multiple sclerosis. Behav Brain Res
2011;220:20–9.
[20] You Z, Luo C, Zhang W, Chen Y, He J, Zhao Q, et al. Pro- and anti-inflammatory cytokines expression in rat's brain and spleen exposed to chronic mild stress: involvement
in depression. Behav Brain Res 2011;225:135–41.
[21] Kaster MP, Gadotti VM, Calixto JB, Santos AR, Rodrigues AL. Depressive-like behavior
induced by tumor necrosis factor-α in mice. Neuropharmacology 2012;62:419–26.
[22] Wilkes S. Bupropion. Drugs Today 2006;42:671–81.
[23] Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL, Soares MB. A new chapter
opens in anti-inflammatory treatments: the antidepressant bupropion lowers
production of tumor necrosis factor-alpha and interferon-gamma in mice. Int
Immunopharmacol 2006;6:903–7.
[24] Kumar B, Kuhad A, Chopra K. Neuropsychopharmacological effect of sesamol in
unpredictable chronic mild stress model of depression: behavioral and biochemical
evidences. Psychopharmacology (Berl) 2011;214:819–28.
[25] Zhu CB, Blakely RD, Hewlett WA. The proinflammatory cytokines interleukin-1
beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006;31:2121–31.
[26] Himmerich H, Binder EB, Künzel HE, Schuld A, Lucae S, Uhr M, et al. Successful
antidepressant therapy restores the disturbed interplay between TNF-alpha system
and HPA axis. Biol Psychiatry 2006;60:882–8.
[27] Luheshi GN, Bluthé RM, Rushforth D, Mulcahy N, Konsman JP, et al. Vagotomy
attenuates the behavioural but not the pyrogenic effects of interleukin-1 in rats.
Auton Neurosci 2000;85:127–32.
[28] Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurol Neurosurg
Psychiatry 2012;83:495–502.
[29] Wegener G, Bandpey Z, Heiberg IL, Mork A, Rosenberg R. Increased extracellular serotonin level in rat hippocampus induced by chronic citalopram is augmented by
subchronic lithium: neurochemical and behavioural studies in the rat. Psychopharmacology (Berl) 2003;166:188–94.
[30] Liu J, Garza JC, Bronner J, Kim CS, Zhang W, Lu XY. Acute administration of leptin produces anxiolytic-like effects: a comparison with fluoxetine. Psychopharmacology
(Berl) 2010;207:535–45.
[31] Felice D, O'Leary OF, Pizzo RC, Cryan JF. Blockade of the GABA(B) receptor increases
neurogenesis in the ventral but not dorsal adult hippocampus: relevance to antidepressant action. Neuropharmacology 2012;63:1380–8.